NTRK1 and cancer: Preclinical study showed that DS-6051b was significantly effective in inhibiting NTRK and ROS1-rearranged cancers, as well as TKI-resistant tumors with secondary kinase domain mutations, such as G2032R mutation in ROS1 and G595R mutation in NTRK1 (103).